Cytochrome P-450 CYP2C19
"Cytochrome P-450 CYP2C19" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cytochrome P-450 enzyme subtype that oxidizes several important groups of drugs including many PROTON PUMP INHIBITORS and ANTICONVULSANTS.
Descriptor ID |
D065731
|
MeSH Number(s) |
D08.244.453.500.700 D08.811.682.690.708.170.500.700 D12.776.422.220.453.500.700
|
Concept/Terms |
Cytochrome P-450 CYP2C19- Cytochrome P-450 CYP2C19
- CYP2C19, Cytochrome P-450
- Cytochrome P 450 CYP2C19
- P-450 CYP2C19, Cytochrome
- CYPIIC19
- S-Mephenytoin 4'-Hydroxylase
- 4'-Hydroxylase, S-Mephenytoin
- S Mephenytoin 4' Hydroxylase
- CYP2C19
|
Below are MeSH descriptors whose meaning is more general than "Cytochrome P-450 CYP2C19".
Below are MeSH descriptors whose meaning is more specific than "Cytochrome P-450 CYP2C19".
This graph shows the total number of publications written about "Cytochrome P-450 CYP2C19" by people in this website by year, and whether "Cytochrome P-450 CYP2C19" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2000 | 0 | 2 | 2 | 2001 | 0 | 1 | 1 | 2002 | 0 | 1 | 1 | 2003 | 0 | 2 | 2 | 2004 | 0 | 1 | 1 | 2006 | 0 | 1 | 1 | 2010 | 0 | 1 | 1 | 2011 | 0 | 1 | 1 | 2012 | 0 | 1 | 1 | 2013 | 0 | 2 | 2 | 2015 | 1 | 0 | 1 | 2016 | 0 | 1 | 1 | 2017 | 1 | 0 | 1 | 2018 | 0 | 2 | 2 | 2019 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Cytochrome P-450 CYP2C19" by people in Profiles.
-
Hicks JK, Bishop JR, Gammal RS, Sangkuhl K, Bousman CA, Leeder JS, Llerena A, Mueller DJ, Ramsey LB, Scott SA, Skaar TC, Caudle KE, Klein TE, Gaedigk A. A Call for Clear and Consistent Communications Regarding the Role of Pharmacogenetics in Antidepressant Pharmacotherapy. Clin Pharmacol Ther. 2020 01; 107(1):50-52.
-
Shakhnovich V, Abdel-Rahman S, Friesen CA, Weigel J, Pearce RE, Gaedigk A, Leeder JS, Kearns GL. Lean body weight dosing avoids excessive systemic exposure to proton pump inhibitors for children with obesity. Pediatr Obes. 2019 01; 14(1).
-
Shakhnovich V, Smith PB, Guptill JT, James LP, Collier DN, Wu H, Livingston CE, Zhao J, Kearns GL. Obese Children Require Lower Doses of Pantoprazole Than Nonobese Peers to Achieve Equal Systemic Drug Exposures. J Pediatr. 2018 02; 193:102-108.e1.
-
Hicks JK, Sangkuhl K, Swen JJ, Ellingrod VL, Müller DJ, Shimoda K, Bishop JR, Kharasch ED, Skaar TC, Gaedigk A, Dunnenberger HM, Klein TE, Caudle KE, Stingl JC. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017 07; 102(1):37-44.
-
Brown JT, Abdel-Rahman SM, van Haandel L, Gaedigk A, Lin YS, Leeder JS. Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHD. Clin Pharmacol Ther. 2016 06; 99(6):642-50.
-
Hicks JK, Bishop JR, Sangkuhl K, Müller DJ, Ji Y, Leckband SG, Leeder JS, Graham RL, Chiulli DL, LLerena A, Skaar TC, Scott SA, Stingl JC, Klein TE, Caudle KE, Gaedigk A. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin Pharmacol Ther. 2015 Aug; 98(2):127-34.
-
Dodgen TM, Hochfeld WE, Fickl H, Asfaha SM, Durandt C, Rheeder P, Drögemöller BI, Wright GE, Warnich L, Labuschagne CD, van Schalkwyk A, Gaedigk A, Pepper MS. Introduction of the AmpliChip CYP450 Test to a South African cohort: a platform comparative prospective cohort study. BMC Med Genet. 2013 Jan 29; 14:20.
-
Hicks JK, Swen JJ, Thorn CF, Sangkuhl K, Kharasch ED, Ellingrod VL, Skaar TC, Müller DJ, Gaedigk A, Stingl JC. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther. 2013 May; 93(5):402-8.
-
Leeder JS, Kearns GL. Interpreting pharmacogenetic data in the developing neonate: the challenge of hitting a moving target. Clin Pharmacol Ther. 2012 Oct; 92(4):434-6.
-
Ogilvie BW, Yerino P, Kazmi F, Buckley DB, Rostami-Hodjegan A, Paris BL, Toren P, Parkinson A. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel. Drug Metab Dispos. 2011 Nov; 39(11):2020-33.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|